NCT03648814View on ClinicalTrials.gov

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions
Glaucoma, NeovascularVascular Endothelial Growth Factor Overexpression
Interventions
PROCEDURE

Intracameral injection

A/C injection of 1.25 mg/0.05 mL bevacizumab

PROCEDURE

Intravitreal injection

Vitreous injection of 1.25 mg/0.05 mL bevacizumab

Trial Locations (1)

90110

RECRUITING

Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University, Hat Yai

All Listed Sponsors
lead

Prince of Songkla University

OTHER